Joel Randolph Hecht

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    Clin Colorectal Cancer 9:95-101. 2010
  2. ncbi request reprint Adjuvant therapy for gastric cancer: a reality at last
    J R Hecht
    Division of Hematology Oncology, UCLA School of Medicine, 2345H PVUB, 10945 LeConte Avenue, Los Angeles, CA 90095, USA
    Curr Gastroenterol Rep 2:478-81. 2000
  3. doi request reprint Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine, University of California, Los Angeles, CA 90404, USA
    Clin Cancer Res 16:2205-13. 2010
  4. doi request reprint A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    J Clin Oncol 27:672-80. 2009
  5. doi request reprint Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice
    J Randolph Hecht
    University of California Los Angeles UCLA Gastrointestinal Oncology Program, David Geffen School of Medicine at UCLA, 10945 Le Conte Avenue, Los Angeles, CA, USA
    Am J Health Syst Pharm 65:S15-21; quiz S22-4. 2008
  6. doi request reprint Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
    J Randolph Hecht
    David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, CA 90404, USA
    J Clin Oncol 29:1997-2003. 2011
  7. ncbi request reprint Successful gastrointestinal cancer drug development
    J Randolph Hecht
    University of California Los Angeles GI Oncology Program, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Semin Oncol 33:S24-7. 2006
  8. ncbi request reprint Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia
    J Randolph Hecht
    UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:13-5. 2003
  9. ncbi request reprint A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma
    J Randolph Hecht
    Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90095, USA
    Clin Cancer Res 9:555-61. 2003
  10. ncbi request reprint Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer
    Joel Randolph Hecht
    Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Mol Imaging Biol 6:208-13. 2004

Detail Information

Publications19

  1. doi request reprint A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    Clin Colorectal Cancer 9:95-101. 2010
    ..This randomized, placebo-controlled phase II study examined pegfilgrastim efficacy and safety in patients with CRC receiving every-2-week chemotherapy...
  2. ncbi request reprint Adjuvant therapy for gastric cancer: a reality at last
    J R Hecht
    Division of Hematology Oncology, UCLA School of Medicine, 2345H PVUB, 10945 LeConte Avenue, Los Angeles, CA 90095, USA
    Curr Gastroenterol Rep 2:478-81. 2000
    ..These results make adjuvant therapy for completely resected gastric carcinoma the new standard of care, except in the uncommon setting of early intramucosal cancers...
  3. doi request reprint Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine, University of California, Los Angeles, CA 90404, USA
    Clin Cancer Res 16:2205-13. 2010
    ..We evaluated the association of tumor EGFR expression levels with outcomes in patients with chemorefractory metastatic colorectal cancer...
  4. doi request reprint A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    J Clin Oncol 27:672-80. 2009
    ..This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC...
  5. doi request reprint Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice
    J Randolph Hecht
    University of California Los Angeles UCLA Gastrointestinal Oncology Program, David Geffen School of Medicine at UCLA, 10945 Le Conte Avenue, Los Angeles, CA, USA
    Am J Health Syst Pharm 65:S15-21; quiz S22-4. 2008
    ....
  6. doi request reprint Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
    J Randolph Hecht
    David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, CA 90404, USA
    J Clin Oncol 29:1997-2003. 2011
    ....
  7. ncbi request reprint Successful gastrointestinal cancer drug development
    J Randolph Hecht
    University of California Los Angeles GI Oncology Program, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Semin Oncol 33:S24-7. 2006
    ....
  8. ncbi request reprint Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia
    J Randolph Hecht
    UCLA School of Medicine, Los Angeles, California, USA
    Oncology (Williston Park) 17:13-5. 2003
    ..Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients...
  9. ncbi request reprint A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma
    J Randolph Hecht
    Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles, California 90095, USA
    Clin Cancer Res 9:555-61. 2003
    ..Therefore, we undertook a trial of the feasibility, tolerability, and efficacy of EUS injection of ONYX-015 into unresectable pancreatic carcinomas...
  10. ncbi request reprint Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer
    Joel Randolph Hecht
    Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Mol Imaging Biol 6:208-13. 2004
    ..To best use the information provided by PET, the nuclear medicine physician and oncologist must both understand the treatment choices available for patients at various stages in the disease...
  11. ncbi request reprint Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
    J Randolph Hecht
    University of California School of Medicine, Los Angeles, CA, USA
    Cancer 110:980-8. 2007
    ..The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies...
  12. ncbi request reprint Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma
    Maria L Delioukina
    University of California at Los Angeles Center for the Health Sciences and Jonsson Comprehensive Cancer Center, Los Angeles, California, USA
    Cancer 94:2174-9. 2002
    ....
  13. doi request reprint Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo
    Zev A Wainberg
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California 90404, USA
    Clin Cancer Res 16:1509-19. 2010
    ....
  14. ncbi request reprint A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
    Carolyn D Britten
    David Geffen School of Medicine at the University of California, Los Angeles 90095, USA
    Cancer Chemother Pharmacol 61:515-24. 2008
    ..This trial was performed to investigate the safety, tolerability, and pharmacokinetics of sunitinib 50 mg daily for 2 weeks followed by a 1-week off period (2/1 schedule)...
  15. ncbi request reprint Panitumumab in colorectal cancer
    Zev A Wainberg
    UCLA Medical Center, Los Angeles, CA 90095, USA
    Expert Rev Anticancer Ther 7:967-73. 2007
    ..Ongoing studies are being performed to determine whether the addition of panitumumab to standard treatment for metastatic colorectal cancer will improve the survival of these patients...
  16. ncbi request reprint Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial
    Fairooz F Kabbinavar
    Division of Hematology Oncology, UCLA School of Medicine, 10945 LeConte Ave, Suite 2338J, Los Angeles, CA 90095 7187, USA
    J Clin Oncol 23:3697-705. 2005
    ..This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan...
  17. pmc Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer
    Diane Lauren Reidy
    Department of Medicine, Division of Solid Tumors, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 1004, New York, NY 10065, USA
    J Clin Oncol 28:4240-6. 2010
    ....
  18. ncbi request reprint A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer
    Zev Wainberg
    GI Oncology Program, David Geffen School of Medicine, University of California, Los Angeles 90095, USA
    Clin Colorectal Cancer 5:363-7. 2006
  19. ncbi request reprint Panitumumab in colon cancer: a review and summary of ongoing trials
    Zev Wainberg
    UCLA Medical Center, Department of Medicine Hematology Oncology, Box 957187, 2338G PVUB, Los Angeles, CA 90095 7187, USA
    Expert Opin Biol Ther 6:1229-35. 2006
    ..Ongoing studies are being performed to determine if the addition of panitumumab to first-line standard treatment for metastatic colorectal cancer will improve the progression-free and overall survival of these patients...